The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
